Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
For patients with advanced gastric and gastroesophageal junction cancer, nivolumab improves overall and progression-free survival.
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in ...
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback